Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase 2 Trial of Selinexor (KPT-330), Bortezomib and Low-dose Dexamethasone Plus Daratumumab (SELIBORDARA) for the Treatment of Patients With Refractory or Relapsed and Refractory Multiple Myeloma

NCT03589222 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT03589222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03589222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase 2 Trial of Selinexor (KPT-330), Bortezomib and Low-dose Dexamethasone Plus Daratumumab (SELIBORDARA) for the Treatment of Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 15, 2018
Completion date
August 31, 2026
Enrollment
62 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma